215 related articles for article (PubMed ID: 25759610)
1. Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.
Kalder M; Hadji P
Breast Care (Basel); 2014 Oct; 9(5):312-7. PubMed ID: 25759610
[TBL] [Abstract][Full Text] [Related]
2. Cancer Treatment-Induced Bone Loss in women with breast cancer.
Hadji P
Bonekey Rep; 2015; 4():692. PubMed ID: 26029361
[TBL] [Abstract][Full Text] [Related]
3. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Hadji P
Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
[TBL] [Abstract][Full Text] [Related]
5. Skeletal health in breast cancer survivors.
Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
[TBL] [Abstract][Full Text] [Related]
6. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
Waqas K; Lima Ferreira J; Tsourdi E; Body JJ; Hadji P; Zillikens MC
J Bone Oncol; 2021 Jun; 28():100355. PubMed ID: 33948427
[TBL] [Abstract][Full Text] [Related]
7. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
8. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
9. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
Hadji P; Aapro MS; Body JJ; Gnant M; Brandi ML; Reginster JY; Zillikens MC; Glüer CC; de Villiers T; Baber R; Roodman GD; Cooper C; Langdahl B; Palacios S; Kanis J; Al-Daghri N; Nogues X; Eriksen EF; Kurth A; Rizzoli R; Coleman RE
J Bone Oncol; 2017 Jun; 7():1-12. PubMed ID: 28413771
[TBL] [Abstract][Full Text] [Related]
10. [Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer.].
Taguchi T
Clin Calcium; 2018; 28(11):1515-1517. PubMed ID: 30374009
[TBL] [Abstract][Full Text] [Related]
11. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Hadji P; Aapro MS; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Gnant M; Guise T; Lipton A
Ann Oncol; 2011 Dec; 22(12):2546-2555. PubMed ID: 21415233
[TBL] [Abstract][Full Text] [Related]
12. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Takahashi S
Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
[TBL] [Abstract][Full Text] [Related]
13. Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer - a retrospective cohort study.
Stumpf U; Kostev K; Siebenbürger G; Böcker W; Hadji P
J Bone Oncol; 2020 Jun; 22():100292. PubMed ID: 32864322
[TBL] [Abstract][Full Text] [Related]
14. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom.
Lester JE; Dodwell D; Horsman JM; Mori S; Coleman RE
Br J Cancer; 2006 Jan; 94(1):30-5. PubMed ID: 16317429
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
Hadji P; Hartenfels M; Kyvernitakis J; Hars O; Baumann KH; Kalder M
Breast Cancer Res Treat; 2012 Jun; 133(3):1089-96. PubMed ID: 22453753
[TBL] [Abstract][Full Text] [Related]
16. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for the management of cancer treatment induced bone loss.
Bertoldo F; Pancheri S; Zenari S; Boldini S
Expert Opin Emerg Drugs; 2010 Jun; 15(2):323-42. PubMed ID: 20377485
[TBL] [Abstract][Full Text] [Related]
18. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
19. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
20. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
